The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors
Objective: to describe musculoskeletal immune-mediated adverse events (iAEs) associated with the therapy of solid tumors with immune checkpoint inhibitors (ICIs, inhibitors of the PD-1/PD-L1 pathway).Patients and methods. 13 patients receiving ICIs therapy with musculoskeletal iAEs were examined. Th...
| Autors principals: | , , , , , |
|---|---|
| Format: | Article |
| Idioma: | Russian |
| Publicat: |
IMA-PRESS LLC
2022-10-01
|
| Col·lecció: | Современная ревматология |
| Matèries: | |
| Accés en línia: | https://mrj.ima-press.net/mrj/article/view/1347 |